A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies

James J. Harding,Richard K. G. Do,Imane El-Dika,Ellen Hollywood,Khrystyna Uhlitskykh,Emily Valentino,Peter Justin Wan,Casey R. Hamilton,Xiaoxing Feng,Amanda Johnston,John S. Bomalaski,Chien-Feng Li,Eileen M. O’Reilly,Ghassan K. Abou-Alfa

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies

2018

James J. Harding
Richard K. G. Do
Imane El-Dika
Ellen Hollywood
Khrystyna Uhlitskykh
Emily Valentino
Peter Justin Wan
Casey R. Hamilton
Xiaoxing Feng
Amanda Johnston
John S. Bomalaski
Chien-Feng Li
Eileen M. O’Reilly
Ghassan K. Abou-Alfa

Purpose Arginine depletion interferes with pyrimidine metabolism as well as DNA damage repair pathways. Preclinical data indicates that pairing pegylated arginine deiminase (ADI-PEG 20) with fluoropyrimidines or platinum enhances cytotoxicity in vitro and in vivo in arginine auxotrophs.

Keywords:

PEG ratio
Pharmacology
In vivo
Arginine deiminase
Pyrimidine metabolism
Cytotoxicity
Hepatocellular carcinoma
Arginine
In vitro
Medicine
Argininosuccinate Synthetase 1
FOLFOX

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations